{"id":"W4200256437","doi":"10.1016/j.annonc.2021.12.002","title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Cilag; Pharmacyclics; Takeda Oncology; Chugai Pharmaceutical; Genentech; MorphoSys; Ono Pharmaceutical; Sanofi; Kyowa Hakko Kirin; Astellas Pharma; Celltrion; Eisai; Seagen; Pfizer; Incyte; Astex Pharmaceuticals; Alexion Pharmaceuticals; Regeneron Pharmaceuticals; Daiichi-Sankyo; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Bayer HealthCare; Celgene; Bristol-Myers Squibb; EUSA Pharma; AstraZeneca; TG Therapeutics; Amgen; Kite Pharma; Meiji Seika Pharma","keywords":"Brentuximab vedotin; Medicine; Oncology; Chemotherapy; Internal medicine; Peripheral T-cell lymphoma; Lymphoma; Peripheral; CD30; Immunology; T cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001004794,0.000186534,0.001595677,0.00005810111,0.00006217809,0.000006319749,0.0001059172,0.0001058842,0.00001848673],"category_scores_gemma":[0.0002996594,0.0001094208,0.0003713914,0.0001738897,0.0002584819,0.00002795321,0.00003124678,0.00004450276,6.547086e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006477998,"about_ca_system_score_gemma":0.0007376601,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003018032,"about_ca_topic_score_gemma":0.000116504,"domain_scores_codex":[0.9979106,0.0003740384,0.0009130778,0.000296995,0.0002640387,0.0002412798],"domain_scores_gemma":[0.9961436,0.001815329,0.0007527872,0.0003926508,0.0008204563,0.00007511736],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9081843,0.04220638,0.000239208,0.00004734143,0.001993685,0.00006996556,0.003473222,0.000003291816,0.001054803,0.0001168543,0.001686844,0.04092414],"study_design_scores_gemma":[0.8464577,0.04322509,0.0007860788,0.00007336475,0.0005754919,0.00001891655,0.002788281,0.00003179191,0.1033586,0.00004416253,0.002560541,0.00007998345],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887781,0.0009151169,0.00002121025,0.003679608,0.0001134504,0.003405718,0.00008059254,0.000008760762,0.002997428],"genre_scores_gemma":[0.9973146,0.0009766256,0.0004542867,0.0003155663,0.00007776936,0.0004010939,0.00004655671,0.00002201666,0.0003914887],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1023038,"threshold_uncertainty_score":0.4462051,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04146925107950564,"score_gpt":0.3740900802665195,"score_spread":0.3326208291870138,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}